Government, NHS, and Pharma Industry Unveil Successor to Voluntary Scheme for Branded Medicines Pric...
Read moreWe're thrilled to announce our participation at ISPOR Europe 2023 in Copenhagen this November. We'll...
Read moreWe summarise the World Orphan Drug Congress Europe 2023 including keynote and panel sessions on EU H...
Read moreWe've updated our 2019 analysis which compares the annual and lifetime treatment costs of the 10 mos...
Read moreThis research aims to understand if just three PICOs are feasible by analysing recent HTA assessment...
Read moreOur research aims to gauge awareness of the new EU HTA process within the pharmaceutical industry in...
Read moreOur study compares and contrasts the evaluation and reimbursement pathways for digital therapeutics ...
Read moreOur study aims to understand how the severity modifier has been implemented so far and its impact on...
Read moreWe outline the challenges pharma companies encounter when launching cell and gene therapies, and ass...
Read moreGermany is reshaping its Ministry of Health to prioritize the prevention of diseases like cancer, de...
Read more